MedTrace Logo

Safety and Efficacy of COVID-19 Prime-boost Vaccine in Bahrain

NCT04993560 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 305

Last updated 2021-10-26

No results posted yet for this study

Summary

Coronavirus disease 2019 (COVID-19) is potentially a deadly disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that targets the lung mainly, resulting in respiratory tract infections in humans. It has developed into a pandemic with serious global public health problems.

Recent research has shown that the new SARS-CoV-2 variants reduces the efficacy of the vaccinations and are predominantly more transmissible or infective. A few countries namely Bahrain, United Arab Emirates, and Turkey have recently started introducing a booster dose following primary two doses of the COVID-19 immunization series.

This study aims to identify which booster dose is more effective; taking a booster dose from the same vaccine initially taken or a booster dose from a different vaccine than initially taken.

Conditions

  • SARS-CoV 2 Infection
  • Covid19

Interventions

BIOLOGICAL

BBIBP-CorV

Inactivated virus COVID-19 vaccine

BIOLOGICAL

BNT162b2

mRNA-based COVID-19 vaccine

Sponsors & Collaborators

  • The National Taskforce for Combatting COVID-19- Kingdom of Bahrain

    collaborator UNKNOWN

  • Bahrain Defence Force Royal Medical Services

    collaborator UNKNOWN

  • Ministry of Health, Bahrain

    collaborator OTHER_GOV

  • Bahrain International Exhibition & Convention Centre

    collaborator UNKNOWN

  • Royal College of Surgeons in Ireland - Medical University of Bahrain

    lead OTHER

Principal Investigators

  • Manaf AlQahtani, Dr. · Royal College of Surgeons in Ireland - Bahrain

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-18
Primary Completion
2021-09-17
Completion
2021-10-19

Countries

  • Bahrain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04993560 on ClinicalTrials.gov